This article has multiple issues. Unsourced material may be challenged the pearson custom library for the biological sciences pdf removed. 120 countries across the globe, including the developed markets of the United States and Europe.
Biocon’s biosimilar products are also sold in both bulk and formulation forms in several emerging markets. Biocon, is engaged in the business of integrated end-to-end drug discovery and development services. Biocon’s formulations for the Indian market straddles Metabolics, Oncology, Immunotherapy, Nephrology and Specialty. HR generalists and general administrators. The operations began out of the garage of a rented house with two employees. Until 1983, the company blended enzymes and supplied them to brewing, textiles, biofuels, animal feed and other such industries across the world.
Shaw decided to focus on biopharmaceuticals rather than enzymes. But Unilever, a major shareholder, did not want to be in the biopharmaceuticals business. Shaw had married in 1998, used his savings to reclaim the entire Biocon stake from Unilever. Biocon soon ventured into the lucrative biopharmaceutical segment. Foreseeing a great opportunity when branded drugs went off patent, they began to develop lovastatin, a cholesterol-lowering drug whose patent expired in 2001.